Patients with Dementia with Lewy bodies (DLB) who also have REM sleep behavior disorder (RBD) present a distinct clinical challenge. The co-occurrence of these two conditions shapes both the choice and the caution required in pharmacological management.
This protocol is for patients with established Dementia with Lewy bodies who present with concurrent REM sleep behavior disorder — a subpopulation at elevated risk of sleep-related injuries and requiring heightened attention to adverse effects on cognition and gait when treatment decisions are made.
In the absence of DLB-specific trial data for this presentation, treatment decisions draw on clinical experience, expert opinion, and evidence-based recommendations developed in related conditions.
Management centres on cautious bedtime pharmacotherapy aimed at reducing the risk of sleep-related injuries. The selection between available options hinges on each patient's cognitive and mobility profile, as agents in this space carry differing risk considerations. The complete structured regimen — including which agents are appropriate, under what circumstances, and in what order — is in the full protocol.
DOI: 10.1212/WNL.0000000000004058
In the absence of DLB-specific trial data for these symptoms, clinicians base their treatment decisions on clinical experience, expert opinion, or evidence-based recommendations developed in other diseases, e.g., cautious bedtime use of clonazepam may reduce the risk of sleep-related injuries in patients with DLB with RBD but carries a risk of worsening cognition and gait impairment, melatonin being a possibly safer option.
View source ↗